Tom Anderson

A 35-year veteran of the biopharma and CPG industries, Tom Anderson has led and been a part of high-growth organizations for much of his career.

Prior to Tom being appointed CEO and Director at SwanBio Therapeutics, he was recruited to Sage Therapeutics, Inc. in 2014 to be the company’s Chief Commercial Strategy Officer and a key member of Sage’s leadership team.

Between 2004 and 2014, Tom was a senior operating (P&L) executive with Shire Pharmaceuticals Group in a number of operational and strategic roles in both rare diseases and specialty pharmaceuticals. During that time, Shire achieved a 5-fold increase in revenues and market cap valuation. Prior to that, Tom was with J&J (Janssen and McNeil Pharmaceutical) in a number of leadership, sales, marketing, and business information roles which experienced transformational growth.

Between 1997 and 2002, Tom served in C-suite and Board roles with market-leading consumer product companies as part of the Claneil Enterprises, Inc. family of companies: President & CEO for Ranir-DCP Corporation, and EVP / COO with Claneil’s Lander Company, Inc. Tom is on the boards of SwanBio Therapeutics, ExpressCells Inc. and a strategic advisor to Sealink International and CEO Trust. He is also an investor partner at Robin Hood Ventures in Philadelphia, PA.

Tom earned an MBA from the University of Notre Dame’s Mendoza College of Business Administration. He received a BS in civil engineering from the P.C. Rossin College of Engineering at Lehigh University